Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation

Cancer Gene Therapy

Volumn 13, Issue 8, 2006, Pages 792-797

  Korn, W M ^a,b   Macal, M ^a,c   Christian, C ^a   Lacher, M D ^a   McMillan, A ^b   Rauen, K A ^a,b   Warren, R S ^a,b   Ferrell, L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO STATE UNIVERSITY   (United States)

Author keywords

Adenovirus based therapies; CAR; Cell adhesion; Gastrointestinal cancer; Tumor differentiation

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR;

ARTICLE; BILE DUCT; CELL ADHESION; CELL INTERACTION; CELL SURFACE; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER CANCER; MAJOR CLINICAL STUDY; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TIGHT JUNCTION; TUMOR DIFFERENTIATION; TUMOR RESISTANCE; VIRAL GENE THERAPY;

ADENOVIRIDAE; CELL COMMUNICATION; CELL DIFFERENTIATION; ENTEROVIRUS; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERCELLULAR JUNCTIONS; NEOPLASMS; RECEPTORS, VIRUS;

ADENOVIRIDAE; COXSACKIEVIRUS;

EID: 33746266715     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700947     Document Type: Article

References (30)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(Suppl 8): S4-S66.
2. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-5312.
3. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079.
4. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
5. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 2001; 98: 15191-15196.
6. Sachs MD, Rauen KA, Ramamurthy M, Dodson JL, De Marzo AM, Putzi MJ et al. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 2002; 60: 531-536.
7. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 2002; 62: 3812-3818.
8. Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, Korn WM. Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci USA 2003; 100: 1943-1948.
9. Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid T. Minimal hepatic toxicity following infusion of adenoviral vector: spatial restriction of CAR receptor in normal liver. Cancer Gene Ther 2006 (in press).
10. Senzer N, Hanna N, Chung T, Nemunaitis J, Rosemurgy A, Javle M et al. Updated response and survival data for TNFerade combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC). Paper presented at: Proc Am Soc Clin Oncology, 2005, Orlando.
11. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389-1397.
12. Venook AP, Warren RS. Therapeutic approaches to metastasis confined to the liver. Curr Oncol Rep 2001; 3: 109-115.
13. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Lee M, Kirn DH. A phase I/II trial of intratumoral endoscopic ultrasound (EUS) injection of Onyx-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Paper presented at: Proc Am Assoc Clin Oncol, 2000.
14. Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy 2001; 8: 308-315.
15. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Therapy 2001; 8: 1618-1626.
16. Warren RS, Kirn DH. Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond. Surg Oncol Clin N Am 2002; 11: 571-588, vi.
17. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005; 12: 673-681.
18. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 813-817.
19. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325-330.
20. Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000; 60: 5031-5036.
21. Tallone T, Malin S, Samuelsson A, Wilbertz J, Miyahara M, Okamoto K et al. A mouse model for adenovirus gene delivery. Proc Natl Acad Sci USA 2001; 98: 7910-7915.
22. Pedersen KB, Nesland JM, Fodstad O, Maelandsmo GM. Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer 2002; 87: 1281-1286.
23. Kanazawa T, Watanabe T, Kazama S, Tada T, Koketsu S, Nagawa H. Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer 2002; 102: 225-229.
24. Pong RC, Lai YJ, Chen H, Okegawa T, Frenkel E, Sagalowsky A et al. Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells. Cancer Res 2003; 63: 8680-8686.
25. Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 2001; 61: 6328-6330.
26. Bruning A, Runnebaum IB. The coxsackie adenovirus receptor inhibits cancer cell migration. Exp Cell Res 2004; 298: 624-631.
27. Anders M, Christian C, McMahon M, McCormick F, Korn WM. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res 2003; 63: 2088-2095.
28. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M et al. TGF-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of CAR in conjunction with reversal of epithelial-mesenchymal-transition. Cancer Res 2006; 66: 1648-1657.
29. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652-660.
30. Smith TA, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, Kaloss M et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 2003; 14: 1595-1604.